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Introduction
Induced pluripotent stem cells (iPSCs) represent a promising con-
tribution to regenerative medicine (1). Despite the regulatory hur-
dles and safety issues involved, reprogramming patients’ cells into 
iPSCs for autologous cell therapy holds potential for degenerative 
disorders such as muscular dystrophies (MDs) (2). Albeit highly het-
erogeneous in their genetic etiology, many forms of MDs cause not 
only progressive deterioration of skeletal muscles, but also chronic 
degeneration of cardiac tissue (3–5). Therefore, MD treatment 
would ideally encompass the regeneration of both striated muscle 
types. Several protocols have been described for the differentiation 
of iPSCs toward cardiac or skeletal muscle progenitors (6, 7), yet a 
single strategy to target both muscle types in vivo remains elusive.
Several reports in recent years have shown that some 
tissue-specific epigenetic biases are maintained in reprogrammed 
cells, thus leading to the so-called epigenetic memory in iPSCs (8, 
9). If sufficiently durable, the epigenetic bias results in a skewed 
iPSC propensity and intrinsically increased differentiation 
toward the parental cell lineage (10). In particular, the intrinsic 
myogenic propensity observed in reprogrammed mesoan-
gioblasts (MABs) (11) might prove useful in driving cell fate in the 
context of skeletal muscle repair. Also, analogous findings have 
recently been reported in the context of cardiac epigenetic mem-
ory (10). However, it is still unknown whether the source-related 
myogenic propensity influences the switch between cardiac and 
skeletal myogenic lineages. Moreover, it is still an open question 
whether such differential propensity would affect the combined 
regeneration of both striated muscle types in vivo.
In this study, we addressed the combined treatment of striated 
muscles by conjugating the iPSC myogenic propensity with the 
prospective isolation of mesodermal iPSC–derived progenitors 
(MiPs) in isogenic settings of murine, canine, and human cells.
Results
Differential myogenic propensity influences iPSC-based chimerism in 
fetal and adult tissues. To exclude interferences caused by genetic 
background or unrelated individual variability, we reprogrammed 
murine iPSCs from isogenic fibroblasts (f-iPSCs) and MABs 
(MAB-iPSCs), both isolated from syngeneic male mice (Supplemen-
tal Figure 1, A and B; supplemental material available online with 
this article; doi:10.1172/JCI82735DS1). Isogenic f- and MAB-iPSCs 
displayed a normal karyotype and comparable expression levels 
of pluripotency markers (Supplemental Figure 1C). In contrast, 
a teratoma assay showed a higher differentiation propensity of 
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satellite cells and MABs in MAB-iPSC–chimeric mice than in 
f-iPSC–chimeric mice during both proliferation and differentia-
tion stages (Figure 2, D–F). Intriguingly, the GFP+ contribution to 
the adult myocardium appeared robust and comparable between 
f- and MAB-iPSCs (Figure 2, G and H). Also, other nonmesoder-
mal postnatal tissues, including liver and skin, did not show sig-
nificant differences in chimerism under steady state and after 
injury (Supplemental Figure 2). Thus, the differential myogenic 
propensity did not affect the pluripotency of MAB-iPSCs, but 
selectively enhanced in vivo chimerism in fetal and adult skeletal 
muscles. In addition, the myogenic bias did not influence iPSC-
driven chimerism in the adult cardiac muscle.
MiPs retain their differential myogenic propensity. In order to 
address the question of whether the myogenic propensity would 
impact the regeneration of striated muscles, we sought a novel pro-
genitor pool that would be amenable to the regeneration of both 
striated muscle types in vivo. To this end, we developed a prospec-
tive sorting strategy for differentiating iPSCs. This approach was 
based on myogenic mesoderm induction (12) and isolation of cells 
that express CD140a, CD140b, and CD44 (Figure 3, A and B), sur-
MAB-iPSCs toward the skeletal muscle lineage compared with that 
of f-iPSCs (Supplemental Figure 1D), thus confirming that we had 
established an isogenic setting of differential myogenic propensity.
To test the impact of iPSC myogenic propensity on tissue 
development, we asked whether f- and MAB-iPSCs differentially 
contribute to chimeric tissues after morula aggregation. We found 
that both GFP+ f- and MAB-iPSCs contributed to tissues of chimeric 
embryos and fertile adults, which displayed variable chimerism in 
coat color and germline transmission (Figure 1, A–D). When assay-
ing the germ layer derivatives during development, MAB-iPSCs 
contributed to a similar extent to fetal brain and liver (Figure 1, 
E and F), but contributed to a significantly greater extent to the 
nascent skeletal muscle fibers as compared with f-iPSCs (Figure 
1, G–I). In the adult tissues, we observed a greater contribution of 
MAB-iPSCs to the postnatal skeletal muscles of chimeric mice in 
both the absence and presence of cardiotoxin-induced regener-
ation (Figure 2, A–C). We then asked whether the iPSC-specific 
contribution to the resident pools of myogenic stem cells was 
different. In accordance with the results observed in adult chime-
ric muscles, we found a higher GFP+ fraction of freshly isolated 
Figure 1. Analysis of myogenic 
propensity of iPSCs in fetal chimeric 
tissues. (A–H) Isogenic GFP+ f- and 
MAB-iPSCs contributed at compa-
rable rates to chimeric morulae and 
blastocysts (A and B) and to chimeric 
fetuses (E14.5) and fertile adults 
(C and D). Rates of GFP+ chimeric 
embryos are reported for each stage 
(n = 5/iPSC line). However, immuno-
fluorescence analysis of fetal tissues 
at E14.5 revealed comparable levels 
of GFP contribution to brain and liver 
(E and F) and unequal contribution 
levels (higher for MAB-iPSCs) to 
nascent somitic myofibers (G and H) 
(n = 6 embryos/iPSC type for fetal 
tissue analyses). Scale bars: ~50 μm 
(A and B) and ~100 μm (C–H). (I) At 
E14.5, qPCR analyses of dissected 
tissues from chimeric fetuses showed 
significantly higher GFP expression 
levels in the trunk muscles of MAB-
iPSC chimeric fetuses compared with 
levels detected in f-iPSC chimeric 
fetuses (*P < 0.05, n ≥3/iPSC type, 
Mann-Whitney U test). Error bars 
represent SD. αFP, α-fetoprotein.
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MiPs, respectively). Intriguingly, the commitment of f- and MAB-
MiPs to the cardiomyogenic lineage appeared robust and compara-
ble, both in coculture with beating neonatal cardiomyocytes and 
after differentiation into immature cardiomyocyte-like cells (Figure 
3C, Supplemental Videos 1–4, and Supplemental Figure 3C). Con-
versely, MAB-MiPs showed a significantly higher propensity for 
skeletal muscle differentiation than did f-MiPs, both in coculture 
with myoblasts (Figure 3C) and after a pulse of Pax3 and Pax7 over-
face markers shared by somatic stem cells from cardiac and skeletal 
muscles (2). When compared with the negative fraction, 
CD140a+CD140b+CD44+ cells showed enrichment in gene and miR 
markers of myogenic mesoderm transition (Figure 3B and Supple-
mental Figure 3, A and B), including Mesp1 (13) and Mir133a (14). 
Therefore, we named these cells MiPs. We then compared the abil-
ity of MiPs to differentiate toward striated muscle lineages in vitro 
when derived from isogenic f- and MAB-iPSCs (f-MiPs and MAB-
Figure 2. Myogenic memory influences contribution to skeletal muscle fibers and resident stem cells. (A–C) Adult chimeric mice showed an increased 
number of GFP+ myofibers in hind limb muscles after regeneration of acute injury (A and B), suggesting chimeric contribution also to the resident stem 
cell pools. In addition, MAB-iPSC–chimeric mice displayed a greater chimeric contribution in both conditions as compared with f-iPSC–chimeric mice 
(C). (D and E) Once purified from the uninjured muscles, primary pools of satellite cells and MABs appeared chimeric at passage 0, with larger GFP+ 
subfractions (arrows) in the cell pools from MAB-iPSC mice, in both proliferation (D) and differentiation (E) stages. Quantitative difference in the GFP+ 
subfractions was confirmed by cytometry (F). (G–N) In contrast, MAB-iPSCs and f-iPSCs did not apparently differ in the GFP+ contribution to the myo-
cardium (G–H). n = 4 mice/iPSC type. *P < 0.05 versus uninjured f-iPSC mice; **P < 0.05 versus injured f-iPSC mice, Kruskal-Wallis and Mann-Whitney 
U tests. Error bars represent SD. Original magnification, ×40 (insets) of selected areas; scale bars: ~100 μm.
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key markers during iPSC-to-MiP differentiation and in isolated 
f- versus MAB-MiPs. Quantitative PCR (qPCR) analyses showed 
that markers of pluripotency (nanog, Oct4) were comparably down-
regulated over time (Supplemental Figure 3E). Markers of mesoder-
mal transition (brachyury, Meox1, Mixl1) were not found to be differ-
expression (Supplemental Figure 3D). In addition, f- and MAB-MiPs 
differentiated to a comparable extent toward other mesodermal lin-
eages such as osteogenic, adipogenic, smooth muscle, and endothe-
lial lineages (Figure 3D). Considering the different behavior in the 
two striated muscle lineages, we analyzed the expression pattern of 
Figure 3. Isolation and characterization of murine MiPs. (A) MiPs were isolated by triple sequential sorting for CD140a, CD140b, and CD44 from GFP+ 
iPSCs with respect to both MiP (f- and MAB-MiPs) and negative (f-neg and MAB-neg) pools. At all steps, positive fraction yields were quantitatively com-
parable between f- and MAB-derived MiPs. (B) SYBR Green– and TaqMan-based qPCR analyses showed that pluripotency factors (Oct4, Sox2, nanog, and 
Lin28) were downregulated, whereas gene and miR markers of mesodermal transition and maturation (brachyury, Mesp1, Tbx1, Mir1, Mir133a, and Mir133b) 
were upregulated in both f- and MAB-MiPs compared with the negative pools (n = 3/MiP type). Error bars represent SD. (C) GFP+ MiPs had comparable 
morphologies during proliferation and differentiated into beating cardiomyocyte clusters in combination with neonatal rat cardiomyocytes at comparable 
rates (original magnification, ×40 for insets of selected areas, showing a mature Sarc αAct pattern). Intriguingly, after coculture with myoblasts, MAB-
MiPs resulted in higher numbers of GFP+ myotubes (arrows) as compared with f-MiPs. n = 4/MiP type. *P < 0.05 versus f-MiPs, Mann Whitney U test. Error 
bars represent SD. (D) Under opportune stimulations in vitro, both f- and MAB-MiPs showed the capacity to undergo osteogenic (alizarin red staining), 
adipogenic (Oil Red O staining), smooth muscle (immunofluorescence staining for calponin; original magnification, ×40 for insets of selected areas, 
showing partial fibrillar organization), and endothelial differentiation (tubular structures formed on a Geltrex layer; left panels) and were characterized 
by deposition of endothelium-specific extracellular matrix (von Willebrand factor [vWF]) and uptake of Dil-Ac-LDL at comparable rates (insets show the 
negative staining control and proliferating cells at equal magnification). n = 4/MiP type. Scale bars: ~100 μm.
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Figure 4. Differential myogenic propensity correlates with specific epigenetic signatures. (A) At both iPSC and MiP stages, we compared the quanti-
tative epigenetic data (methylation percentage by 1-way ANOVA and histone mark enrichment by 2-way ANOVA) of f- and MAB-derived cells in specific 
loci using a hierarchical system of three queries. Query 1 (Q1) addressed the difference between f- and MAB-derived cells within the same stage. When 
Q1 = *, we addressed the difference between each cell population and the related parental cells within the same progeny (Q2a, f progeny; Q2b, MAB 
progeny). When Q2a = Q2b = NS, the bias was considered inherited (§); when Q2a = Q2B = *, the bias was considered remodeled ($); finally, in cases 
of nonunivocal results (Q2a ≠ Q2b), the bias was considered stochastic (#). This statistical categorization was applied to both bisulphite sequencing 
(DNA methylation; data expressed as a percentage of methylated CpGs) and ChIP-qPCR data (H3K marks; data expressed as a percentage of input) 
of CpG islands of target genes. (B) Following this statistical model, the pluripotency marker nanog showed stage-specific changes in epigenetic cues, 
with no progeny-related bias (Q1 = NS). (C) The mesodermal marker brachyury showed inherited, progeny-related bias in methylation (§), but remod-
eled biases in histone marks ($). MAB-iPSCs and MAB-MiPs showed more permissive/activating epigenetic cues (lower methylation, higher levels of 
H3K4me2 and H3K27ac). (D) The skeletal myogenesis marker Pax7 presented inherited biases in both methylation and histone marks at both iPSC (§) 
and MiP (§) stages. MAB-derived cells showed a durable bias in lower methylation and permissive/activating histone marks. (E) Conversely, the cardiac 
myogenesis marker Tbx5 showed stage-specific shifts in methylation and histone marks, with no significant progeny-related bias (Q1 = NS). Both MiP 
types showed low methylation levels and enrichment in H3K27ac. n = 3/cells pool. *P < 0.05, 1-way ANOVA with Bonferroni’s multiple comparisons test 
for DNA methylation analysis; 2-way ANOVA with Bonferroni’s multiple comparisons test for histone mark analysis. All analyses included data from 
isogenic clones from 3 syngeneic individuals. fibrobl, fibroblasts; mCpGs, methylated CpGs.
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entially patterned (with the exception of Mixl1) during bulk 
differentiation, but were found to be differentially expressed in iso-
lated MiPs (Supplemental Figure 3F). In contrast, markers of skele-
tal myogenesis (Pax3, Pax7, Desm) were differentially patterned dur-
ing iPSC differentiation and at the MiP stage (Supplemental Figure 
3G). Conversely, expression levels of cardiac myogenesis markers 
(Tbx5, Gata4, Flk1) appeared comparable during differentiation and 
in isolated MiPs (Supplemental Figure 3H). Consistent with the 
notion of epigenetic memory (15), we sought to determine whether 
the differential myogenic propensity correlated with progeny-spe-
cific epigenetic cues across somatic, iPSC, and MiP stages. We 
focused our analyses on DNA CpG methylation and on histone 3 
lysine (H3K) marks — specifically, trimethylation of lysine 9 
(H3K9me3), dimethylation of lysine 4 (H3K4me2), and acetylation 
of lysine 27 (H3K27ac). DNA CpG methylation is a broadly investi-
gated trait for epigenetic regulation (16). H3K9me3 is a repressive 
histone marker associated with bias retainment and differentiation 
in striated muscle cells (17, 18). H3K4me2 marks a permissive state 
for genes promoting both skeletal (19) and cardiac (20) myogenic 
lineages, and the H3K9me3/H3K4me2 ratio on specific promoters 
has been associated with clinical parameters of facioscapulohu-
meral MD (21). H3K27ac has been described as a predictive activat-
ing marker for CpG-related promoters in muscle cells as well (22). 
Given the previous indications that epigenetic biases are located in 
key upstream promoters in the context of intrinsic myogenic pro-
pensity (11), we narrowed our analyses of DNA methylation and 
H3K signature patterns to the CpG islands upstream of the tran-
scription start sites of the aforementioned key markers. Overall, 
parental somatic cells exhibited a prevalently “closed” (high methy-
lation, prevalence of H3K9me3) state for pluripotency and cardio-
myogenic markers, whereas MAB progenies showed a significantly 
more “open” (low methylation, prevalence of H3K4me2 or 
H3K27ac) state for skeletal myogenic genes and brachyury (Figure 4 
and Supplemental Figures 4–6). We then applied a hierarchical 
statistical system to quantitatively assess the progeny-related 
retainment of specific patterns of methylation and H3K marks 
across iPSC and MiP stages. First, the epigenetic patterns were com-
pared between f- and MAB-iPSCs and between f- and MAB-MiPs 
(query 1 [Q1]). Then, the epigenetic patterns were compared 
between stage-specific and parental cells (Q2) for both progenies 
(Q2a, f-derived cells; Q2b, MAB-derived cells). When the epige-
netic trait pattern was significantly different between f- and 
Figure 5. In vivo combined regeneration of cardiac and skeletal muscles. (A) Schematic representation of the parallel delivery system of GFP+ f- and 
MAB-MiPs injections into the myocardium and both femoral arteries of Sgcb-null dystrophic cardiomyopathic mice 3 months after birth. Four weeks 
after injection, both f- and MAB-MiPs comparably engrafted the myocardium, whereas MAB-MiPs engrafted the hind limb muscles (shown are tibialis 
anterior muscles) markedly more than did f-MiPs, as shown by stereofluorescence (B) and immunostaining (C). (D)Accordingly, immunofluorescence 
analysis showed comparable numbers of GFP+Sgcb+ cardiomyocytes in the heart, whereas a markedly greater number of GFP+Sgcb+ fibers were observed 
in MAB-MiP–treated muscles compared with those in f-MiP controls (gastrocnemius muscles are shown in D). n = 8 mice/group.
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MAB-derived cells at the iPSC or MiP stage (Q1=*), we further set 
Q2 conditions to score whether the bias was retained or remodeled 
from the parental cell stages, or stochastically introduced during 
stage-to-stage cell transition. When the bias was not significantly 
different from that of the parental cells in both progenies (Q2a = 
Q2b = NS), the bias was considered inherited (§); whereas it was 
considered remodeled ($) when the bias was significantly different 
from that of the parental cells in both progenies (Q2a = Q2b =*). 
When the comparison with the parental cells was not univocal 
between progenies (Q2a ≠ Q2b), the bias was considered stochastic 
(#) (Figure 4A). According to bisulphite sequencing (DNA methyla-
tion levels) and ChIP-qPCR (H3K mark enrichment) analyses, the 
epigenetic state of nanog and Oct4 appeared, as expected, to be 
open in iPSCs and partially closed in MiPs, with no bias discriminat-
ing between f- and MAB-derived progenies (Q1 = NS; Figure 4B and 
Supplemental Figure 5A). Interestingly, mesodermal transition 
markers showed nonunivocal trends in epigenetic regulation. 
Indeed, analysis of brachyury showed an inherited bias in DNA 
methylation and a remodeled bias in histone marks in both iPSCs 
and MiPs (Figure 4C). Meox1 showed progeny-related biases only in 
DNA methylation that were inherited in iPSCs and remodeled in 
MiPs (Supplemental Figure 5B). Mixl1 showed remodeled biases in 
H3K marks at both stages (Supplemental Figure 5C). In line with 
skewed gene expression regulation, the skeletal myogenic markers 
Pax7, Pax3, and Desm were characterized by inherited biases in 
DNA methylation and H3K marks at both iPSC and MiP stages (Fig-
ure 4D and Supplemental Figure 5, D and E). Conversely, the epige-
netic state of Tbx5, Gata4, and Flk1 appeared open in iPSCs and 
MiPs, with no bias discriminating against f- and MAB-derived prog-
enies (Q1 = NS; Figure 4E and Supplemental Figure 6, A and B). 
Considering the difference in expression and the inherited epige-
netic biases for brachyury and skeletal myogenic genes such as 
Figure 6. Functional regeneration of skeletal, but not cardiac, muscles is influenced by MiP myogenic propensity. (A) WB and densitometric analyses 
of Sgcb protein in MiP-injected cardiac and skeletal muscle 4 weeks after injection. Consistent with the immunofluorescence data, Sgcb levels were 
comparable in MiP-treated myocardium samples and significantly higher in MAB-MiP–treated skeletal muscle (tibialis anterior) biopsies. n = 3/group. 
*P < 0.05, Mann-Whitney U test. Error bars represent SD. (B) 3D echocardiographic results showed cardiac functionality that was significantly and 
comparably ameliorated by f- and MAB-MiPs. (C) In contrast, the amelioration in treadmill performance (run time) and serum CK levels was markedly 
increased in MAB-MiP– versus f-MiP–treated mice. n = 8 mice/group. *P < 0.05 versus sham; **P < 0.05 versus sham and f-MiPs, Kruskal-Wallis and 
Mann-Whitney U tests. Each data point refers to 1 animal. Error bars represent average values. Accordingly, 8 weeks after injection, the absolute force 
measurement in EDL muscles under iterated bouts of isometric contraction showed significant improvement in the force curve in f-MiP–injected ver-
sus sham-injected mice, and in MAB-MiP– versus f-MiP–injected mice. n = 5 mice/group. #P < 0.05 versus sham; ##P < 0.05 versus sham and f-MiPs, 
2-way ANOVA. Data represent average values expressed as a percentage of input sham (average value at approximately 1 for sham muscles); ribbons 
represent the interval of SD. (D) qPCR analysis of heart, skeletal muscles, and filter organs showed barely detectable GFP signal in liver, lungs, spleen, 
and kidneys 8 weeks after delivery of f- and MAB-MiPs. Immunofluorescence analysis revealed the occasional occurrence (generally ≤2 per section) of 
GFP+α-SMA+ small vessels in filter organs of MiP-treated animals (inset shows the spleen of an f-MiP–injected animal; n = 5 mice/cohort), suggesting 
very limited levels of off-target engraftment. Insets, ×40 magnification of selected areas; scale bars: ~100 μm.
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Pax7, we asked whether restoring the expression of these genes in 
f-MiPs to levels comparable to those in MAB-MiPs induces a corre-
sponding increase in myogenic propensity. We optimized transfec-
tion conditions to pulse f-MiPs with transient overexpression of 
both genes to levels similar to those in control MAB-MiPs (Supple-
mental Figure 6C), and we then assessed their myogenic propensity 
in coculture with myoblasts or via spontaneous differentiation. 
While overexpression of brachyury did not induce significant effects 
and Pax7 pulsing induced only limited effects, we found, intrigu-
ingly, that the combination of both gene pulses significantly amelio-
rated the myogenic propensity of f-MiPs to levels similar to those 
detected in control MAB-MiPs (Supplemental Figure 6, D and E). As 
expected, pulsing MAB-MiPs under the same transfection condi-
tions resulted in higher levels of gene expression and even aug-
mented the myogenic propensity (Supplemental Figure 6, D and E). 
Thus, the differential myogenic propensity of MAB-iPSCs and 
MAB-MiPs correlated with inherited biases in DNA methylation 
and H3K marks of key skeletal myogenesis marker genes. Also, 
altering expression levels of both mesodermal and skeletal myo-
genic genes in f-MiPs to levels comparable to those in MAB-MiPs 
correlated with increased myogenic propensity. In addition, the car-
diomyogenic markers appeared not to be progeny biased and were 
marked by a permissive/open epigenetic state in MiPs.
Combined functional regeneration of striated muscles in dystrophic 
mice. We then addressed the relevance of MiP technology for in vivo 
simultaneous regeneration of both striated muscle types. We tested 
isogenic GFP+ f- and MAB-MiPs for combined repair of cardiac and 
skeletal muscles in dystrophic cardiomyopathic Sgcb-null mice (ref. 
23, Figure 5A, and Supplemental Figure 7A). Four and eight weeks 
after parallel delivery of 5 × 105 cells to the myocardium and femo-
ral arteries, the cardiac muscles appeared extensively and compara-
bly engrafted by f- and MAB-MiPs, whereas the hind limb skeletal 
muscles showed greater engraftment of MAB-MiPs (Figure 5, B and 
C). Immunostaining-based quantitation of GFP+ areas revealed that 
f- and MAB-MiPs engrafted 28.24% ± 1.90% and 28.64% ± 1.98% 
of the left ventricle wall (average ± SD; n = 8 mice/group; P = 0.23 
[NS], Mann-Whitney U test), respectively. Conversely, quantitation 
of GFP+ fibers in the gastrocnemius muscles revealed a significant 
difference in engraftment between f-MiPs (9.30% ± 0.74%) and 
MAB-MiPs (31.33% ± 2.20%; P = 0.0002). Consequently, we asked 
whether the engraftment paralleled the restoration of the missing 
protein. The reappearance of Sgcb was comparable in f-MiP– and 
MAB-MiP–engrafted hearts, whereas it appeared significantly 
increased in MAB-MiP–engrafted skeletal muscles (Figure 5D and 
Figure 6A). Likewise, fibrotic scars in both muscle types appeared 
to be comparably reduced (Supplemental Figure 7B). Furthermore, 
we sought to determine whether the molecular and histological 
features of MiP-driven regeneration matched the functional out-
come. At 4 and 8 weeks after delivery, 3D echocardiography showed 
improved cardiac function, reduced hypertrophic remodeling, and 
decreased left ventricle dilation to a similar extent in f-MiP– and 
MAB-MiP–treated cohorts (Figure 6B and Supplemental Figure 7, 
C and D). However, performance on the treadmill was significantly 
better in MAB-MiP–treated mice compared with f-MiP–treated mice 
at both time points. In addition, creatine kinase (CK) serum levels 
were lower in MAB-MiP–injected mice than in f-MiP–injected mice 
under resting conditions. Also, 8 weeks after delivery, the curve of 
Figure 7. Single-cell clone characterization of f- and MAB-MiPs. (A) 
Murine GFP+ MiPs were single-cell cloned by limiting dilution. (B) qPCR 
analysis showed significant upregulation of mesodermal markers 
(brachyury, Meox1, Mixl1) and skeletal myogenic markers (Pax7, Pax3, 
Desm), but no significant differences in cardiomyogenic markers (Tbx5, 
Gata4, Flk1), recapitulating what was observed in whole-cell pools. Data 
represent relative expression values (absolute expression normalized to 
the housekeeping gene), and each data point refers to the average value 
of 1 clone; n = 8 clones/MiP type. *P < 0.05, unpaired t test.
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of injected MiPs in filter organs. In order to more stringently eval-
uate the myogenic propensity of f-MiPs versus that of MAB-MiPs in 
vivo, we obtained single-cell clones of GFP+ MiPs (Figure 7A). qPCR 
analysis of mesodermal, skeletal, and cardiac myogenic markers 
in single MiP clones confirmed the expression patterns previously 
evaluated in whole-cell pools (Figure 7B). We then injected Sgcb- 
null mice with single-cell MiP clones, following the same parallel 
delivery procedure. Four weeks after delivery, engraftment (GFP+ 
myocytes) and regeneration (GFP+Sgcb+ myocytes) rates were com-
parable in cardiac muscles (Figure 8A), but these rates were signifi-
cantly higher in the hind limb skeletal muscles of mice injected with 
absolute force developed by extensor digitorum longus (EDL) mus-
cles under iterated bouts of isometric contraction was increased 
to a significantly higher extent in MAB-MiP–injected mice than in 
f-MiP–injected mice when compared with that observed in sham 
controls (Figure 6C and Supplemental Figure 7D). Finally, we ana-
lyzed off-target engraftment of MiPs in filter organs. Eight weeks 
after delivery, qPCR analysis indicated barely detectable levels of 
GFP in the liver, lungs, spleen, and kidneys of MiP-injected mice 
as compared with levels in skeletal and cardiac muscles. Histolog-
ical analysis of these organs showed a rare presence of GFP+ small 
vessels (Figure 6D), suggesting very limited ectopic engraftment 
Figure 8. Single-cell MiP clones recapitulate the differential propensity for skeletal muscle regeneration. (A) Four weeks after injection, both f- and 
MAB-MiPs comparably engrafted the left ventricular wall, with no significant differences in GFP+ (engrafted) or GFP+Sgcb+ (regenerated) cardiomyocytes. 
(B) MAB-MiP clones engrafted and regenerated the hind limb muscles (shown are gastrocnemius muscles) to a significantly greater extent than did f-MiP 
clones, as quantitated in GFP+ and GFP+Sgcb+ fibers. n = 5 mice/cohort. *P < 0.05, Mann-Whitney U test. (C) Masson’s trichrome staining revealed con-
spicuous fibrotic scars (black arrows) in sham mice that were partially reduced in f-MiP–injected mice and even more reduced in MAB-MiP–injected mice 
(shown are gastrocnemius muscles; n = 5 mice/cohort). (D) Immunostaining for slow (arrowheads) and fast (arrows) fibers showed that both fiber types 
were engrafted in f-MiP– and MAB-MiP–injected mice (shown are gastrocnemius muscles). Quantitation of relative fiber type composition of whole-mus-
cle sections and engrafted fibers revealed no significant differences among cohorts (data are related to gastrocnemius and tibialis anterior muscles; n = 5 
mice/cohort; Kruskal-Wallis and Mann-Whitney U tests). (E) MAB-MiP clones engrafted the resident pool of Pax7+ satellite cells to a significantly greater 
extent than did f-MiPs. n = 5 mice/cohort. *P < 0.05, Mann-Whitney U  test. Error bars represent SD. Scale bars: ~100 μm (A–C) and 50 μm (D and E).
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striated muscle types after combined administration in vivo. Intrigu-
ingly, the myogenic propensity of MAB-MiPs did not influence car-
diac muscle regeneration, but correlated with enhanced contribu-
tion to skeletal muscle repair.
Translation into canine settings. In order to gain translational 
insight into our system of combined striated muscle regenera-
tion and skeletal muscle bias, we used the same MiP experimen-
tal protocol in a canine model. Golden retriever MD (GRMD) 
dogs still constitute the foremost preclinical large-animal model 
for novel MD regenerative treatments (24). In light of this fact, 
we isolated isogenic skin fibroblasts and skeletal muscle MABs 
from age-matched WT and GRMD dogs (Supplemental Figure 8, 
A and B), adapting the methods previously reported for human 
MABs (25). Given the strong similarity between canine repro-
gramming factors and human orthologs, we reprogrammed the 
MAB-MiP clones than in those of mice injected with f-MiP clones 
(Figure 8B). Fibrotic scars in the skeletal muscles appeared simi-
larly reduced in MiP-injected hind limbs (Figure 8C). We then asked 
whether the progeny of MiP clones influenced engraftment toward 
a specific fiber type (slow or fast). Immunostaining analyses of slow 
and fast fibers in mixed muscles (i.e., gastrocnemius) revealed that 
both slow and fast fibers were engrafted by f- and MAB-MiPs. Also, 
we found no significant quantitative differences between sham and 
MiP-injected mice in the relative fiber type composition of whole 
muscles and engrafted fibers (Figure 8D). Finally, we assessed the 
contribution of MiP clones to the resident pool of Pax7+ satellite 
cells. Consistent with the engraftment and regeneration data, the 
GFP+Pax7+ fraction of resident satellite cells was significantly higher 
in MAB-MiP–treated muscles than in f-MiP–treated muscles (Figure 
8E). Thus, murine MiPs were able to simultaneously regenerate both 
Figure 9. Translation of MiP-based in vivo approach in xenograft settings with canine cells. (A) Experimental plan of canine MiP dual injections in immu-
nodeficient mice with heart damage induced by transient coronary artery ligation (CAL) and in the hind limb skeletal muscles induced by i.m. cardiotoxin 
(CTX) injections. Injected GFP+ f- and MAB-MiPs were isolated from the same WT donor (number 2). Four weeks after injection, canine f- and MAB-MiPs 
engrafted the myocardium at comparable levels, but not the hind limb muscles, where MAB-MiP engraftment rates appeared higher, as shown by ste-
reofluorescence (B) (shown are tibialis anterior muscles) and immunostaining (C) (shown are gastrocnemius muscles). (D) Immunofluorescence analysis 
revealed comparable levels of GFP+ canine-specific dystrophin+ cardiomyocytes in MiP-treated animals, but significantly greater numbers of GFP+dystro-
phin+ myofibers in MAB-MiP-treated hind limb muscles. n = 7 mice/group. (E) qPCR analyses consistently showed that GFP expression levels were similar 
in injected hearts, yet increased in skeletal muscles (tibialis anterior), and that dystrophin levels followed a similar pattern. n = 7 mice/group. **P < 0.05 
versus f-MiPs, unpaired t test. Error bars represent SD. Original magnification, ×40 for insets of selected areas; scale bars: ~100 μm.
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etal muscle injury induced by local cardiotoxin injection (Figure 
9A). Four weeks after parallel delivery, canine f- and MAB-MiPs 
appeared comparably engrafted into the myocardium, whereas 
MAB-MiPs engrafted into skeletal fibers with higher efficiency 
than did f-MiPs (Figure 9, B and C). Immunostaining-based quan-
titation of GFP+ areas revealed that f- and MAB-MiPs engrafted 
28.82% ± 1.39% and 27.68% ± 2.44% of the left ventricular wall 
(n = 7 mice/group; P = 0.71 [NS], Mann-Whitney U test). Conversely, 
quantitation of GFP+ fibers in the gastrocnemius muscles revealed 
a significant engraftment difference between f-MiPs (10.59% ± 
7.71%) and MAB-MiPs (33.98% ± 1.83%; P = 0.0006). We thus 
asked whether the engraftment paralleled the regeneration, eval-
uated as expression of nonmurine dystrophin. Accordingly, MiP- 
injected tissues showed comparable levels of dystrophin in 
engrafted ventricles and higher levels in MAB-MiP–treated versus 
f-MiP–treated skeletal muscles (Figure 9, D and E). Interestingly, 
f- and MAB-MiPs comparably counteracted adverse ischemic 
remodeling (Figure 10, A and B, and Supplemental Figure 10A), 
whereas MAB-MiPs contributed at significantly greater numbers 
of cells to the resident progenitor pools (satellite cells and MABs) 
in treated skeletal muscles as compared with f-MiPs (Figure 
10C). Subsequently, we sought to conjugate the MAB-MiP–based 
approach with genome editing and mutation correction. We used 
tailored TALENs and donor matrix plasmids (27) to specifically 
correct the GRMD mutation in canine dystrophic MAB-iPSCs 
(Supplemental Figure 10B). After single-cell dilution and targeting 
validation, corrected MAB-iPSCs were also checked for pluripo-
canine cells with retroviral vectors carrying the human factors 
OCT4, SOX2, KLF4, and cMYC. After individual clone selec-
tion and expansion, canine iPSCs exhibited human iPSC-like 
(hiPSC-like) morphology, homogeneous expression of endoge-
nous pluripotency markers, and a normal karyotype (Supplemen-
tal Figure 8C). We then tested GFP+ WT and GRMD iPSCs for 
skeletal muscle memory using the teratoma assay. Both WT and 
GRMD MAB-iPSCs showed greater differentiation toward skel-
etal muscle derivatives as compared with isogenic f-iPSC con-
trols (Supplemental Figure 8D). Furthermore, we asked whether 
canine MiPs recapitulated the characteristics observed in murine 
MiPs. Canine MiPs appeared highly similar to murine MiPs with 
regard to morphology, molecular characteristics, and in vitro dif-
ferentiation ability (Supplemental Figure 9, A–C). Consistent with 
our previous findings, canine MAB-MiPs showed a higher pro-
pensity toward skeletal muscle differentiation than did f-iPSCs 
in both WT and GRMD genotypes (Supplemental Figure 9D). 
Thus, the differential myogenic propensity was also identifiable 
in isogenic canine iPSCs from both WT and dystrophic animals 
and appeared durable in canine MAB-MiPs.
Assessment of canine MiP potential and GRMD correction. We 
then sought to investigate the in vivo regenerative potential of 
canine MiPs in an immunodeficient murine model (26) of paral-
lel acute damage in both striated muscle types. Similarly to the 
murine MiP protocol, we administered isogenic WT canine f- and 
MAB-MiPs to age-matched Rag2-null γc-null mice following myo-
cardial injury induced by ischemia/reperfusion and hind limb skel-
Figure 10. Canine MiPs regenerate the heart and engraft within resident stem cell pools in the skeletal muscle. (A) Masson’s trichrome staining 
of whole-heart transversal sections showed dramatic amelioration of the outer left ventricular wall in terms of fibrosis and cardiomyocyte mass. (B) 
Accordingly, 3D echocardiographic results showed comparable improvement in adverse ischemic remodeling by f- and MAB-MiPs. n = 7 mice/group. 
*P < 0.05 versus sham, Kruskal-Wallis and Mann-Whitney U tests. Each data point refers to 1 animal. Error bars represent average values. (C) Immu-
nofluorescence imaging and quantitation showed that MAB-MiPs contributed in greater numbers to the quiescent pools of satellite cells (Pax3+, 
underneath the sarcolemma) and MABs (AP+, juxtaposed with small vessels) in engrafted hind limb muscles than did f-MiPs (arrowheads indicate 
GFP– resident cells; arrows indicate GFP+ engrafted resident cells). n = 7/group. **P < 0.05 versus f-MiPs, Mann-Whitney U test. Scale bar: ~50 μm.
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via parallel delivery into Sgcb-null Rag2-null γc-null mice (Figure 
11E). Four weeks after injection, dystrophin was detected at com-
parable levels in WT- and corrected MiP–engrafted cardiac and 
skeletal muscles, albeit with interindividual variability (Figure 
11, F and G). In addition, treadmill performance, serum CK levels 
under resting conditions, and absolute force in response to iterated 
bouts of isometric contraction were ameliorated to a comparable 
extent in mice injected with WT or corrected MiPs as compared 
with sham-injected mice (Figure 11H). Thus, the MiP-based dual 
treatment of striated muscles appeared translatable to xenograft, 
tency marker expression and normal karyotype (Supplemental 
Figure 10C). Once isolated and cocultured with myoblasts, cor-
rected GRMD MAB-MiPs efficiently rescued dystrophin expres-
sion as compared with that observed in WT and uncorrected con-
trols (Figure 11, A–D). To prove TALEN-based MiP correction of 
chronic muscle wastage in vivo, we obtained a suitable dystrophic, 
xenograft-permissive model. We crossed Sgcb-null and Rag2-null 
γc-null mice and validated the dystrophic degeneration in Sgcb-null 
Rag2-null γc-null striated muscles (Supplemental Figure 11A). We 
then tested GFP+ WT, GRMD, and isogenic corrected MAB-MiPs 
Figure 11. TALEN-mediated correction of GRMD mutation and application in vivo. Proliferation of WT, GRMD, and TALEN-corrected MAB-MiPs was indis-
tinguishable (A), yet canine-specific dystrophin was detected only when WT and corrected MiPs were differentiated in low-ratio coculture with murine 
myoblasts, as shown by immunofluorescence (B), qPCR (C), and WB (D) analyses. (E) Schematic representation of the in vivo proof of TALEN-based canine 
MiP correction in dystrophic immunodeficient mice. Four weeks after injection, all MAB-MiPs robustly engrafted cardiac and skeletal muscles of Sgcb-null 
Rag2-null γc-null mice, but dystrophin was detected at comparable levels only in WT and corrected MiP–engrafted tissues, as shown by immunofluores-
cence imaging (F) and WB and densitometric analyses (G), albeit with interindividual variability. n = 4 mice/group. Kruskal-Wallis and Mann-Whitney U 
tests. (H) Four weeks after in vivo delivery, WT and corrected MAB-MiPs comparably induced improved treadmill performance, decreased serum CK levels, 
and increased the absolute force curve upon iterated isometric contractions. n = 4 mice/cohort. *P < 0.05 versus sham, Kruskal-Wallis and Mann-Whitney 
U tests. Each data point represents 1 animal. n = 4 mice/cohort. #P < 0.05 versus sham, 2-way ANOVA. Data represent average values, expressed as a 
percentage of input sham (average value at approximately 1 for sham muscles); ribbons depict the interval of SD. Scale bars: ~100 μm.
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ogy and patterns of pluripotency marker expression (Supplemen-
tal Figure 11C). Consistent with murine and canine iPSCs, human 
MAB-iPSCs also spontaneously showed a higher propensity toward 
the skeletal muscle lineage compared with isogenic f-iPSCs, 
as observed in teratomas (Supplemental Figure 11D) and during in 
vitro differentiation after pulsed expression of PAX7 and MEF2C 
(Supplemental Figure 11E). Finally, once derived from these iPSCs, 
human isogenic f- and MAB-MiPs showed comparable levels of 
cardiomyogenic differentiation toward immature cardiomyocyte–
canine-in-murine settings. Also, the MAB-related myogenic bias 
influenced skeletal myogenic, but not cardiomyogenic, regenera-
tion of canine MiPs. Finally, the MiP-based approach proved suit-
able for targeted MD correction in vivo.
Proof of principle using isogenic human cells. Finally, as proof of 
principle in human settings, we isolated isogenic fibroblasts and 
MABs from fetal biopsies of skin and muscle tissues, respectively 
(Supplemental Figure 11B). After reprogramming with retroviral 
vectors, human f- and MAB-iPSCs showed comparable morphol-
Figure 12. In vitro characterization of myogenic propensity in human MiPs. (A) After triple sequential sorting for CD140a/CD140b/CD44 from iPSC 
clones obtained from 3 independent donors, isogenic human GFP+ f- and MAB-MiPs displayed similar morphology. Consistent with murine and canine 
cells, f- and MAB-MiPs showed comparable efficiency in their differentiation toward cardiomyocyte-like (cTnI+-Cx43+) cells, whereas human MAB-
MiPs showed greater myogenic potential in coculture with C2C12, evaluated as a propensity toward GFP+ chimeric myotubes (arrows). n = 4/MiP type. 
*P < 0.05 versus f-MiPs, Mann Whitney U test. Error bars represent SD. (B) Differentiation toward osteogenic, adipogenic, and endothelial lineages 
was robust and comparable between human f- and MAB-MiPs. n = 4/MiP type. Insets in B show negative staining control and proliferating cells at 
equal magnification (original magnification, ×20). (C) After single-cell clonal expansion, f-MiP and MAB-MiP clones were cocultured with cardiomyo-
cytes and myoblasts of rodent origin. Immunostaining for human-specific Sarc αAct showed that the human-specific sarcomeric protein specifically 
colocalized with GFP+ engrafted cardiomyocyte clusters and myotubes (arrows), thus supporting the notion that MiP fusion correlates with terminal 
differentiation. n = 3/MiP type. Scale bars: ~100 μm. 
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model because its myogenic bias has already been partially docu-
mented (11), and its intrinsic propensity was hypothesized to be of 
potential relevance in the context of muscle repair. For a starting 
somatic cell population, we consistently isolated MABs as an alka-
line phosphatase–sorted (AP-sorted) subfraction of pericytes in all 
three species. Although the mechanisms are still largely unknown, 
AP apparently marks a myogenic subset of resident pericytes in 
the skeletal muscle that are locally committed to skeletal myogen-
esis, especially in vivo (30). Importantly, the intrinsic myogenic 
potential of resident and injected murine MABs for differenti-
ation into skeletal muscle tissue has been confirmed in a trans-
genic, inducible genetic system relying on AP::CreERT2 recombi-
nase (31). Also, although restricted to MABs of embryonic origin, 
genetic ablation of Pax3 blunts the skeletal myogenic potential of 
MABs (32). Moreover, by means of a dedicated scaffold, murine 
MABs were shown to generate functional artificial skeletal muscle 
tissue in vivo (33). Thus, resident AP+ MABs from skeletal mus-
cles appear intrinsically myogenic, probably to a species-specific 
variable extent, and, as shown by the present work, this intrinsic 
myogenic bias appears durable after reprogramming in murine, 
canine, and human settings. We did not use satellite cells as a 
source for iPSCs, as it was already reported that committed myo-
blasts are extremely inefficient to reprogram and that less com-
mitted, multipotent resident stem cells from the skeletal muscle 
were more efficiently reprogrammable (34). Furthermore, albeit 
demonstrated in an unrelated lineage, i.e., pancreatic adenocar-
cinoma, it has been shown that iPSCs generated from undifferen-
tiated cells (tumor cells) produced more mature, lineage-specific 
derivatives when compared with iPSCs generated from differenti-
ated cells (margin cells), thus indicating the possibility of efficient 
propensity retainment from less committed cells (35). Besides the 
differences in myogenic commitment, we did not observe signifi-
cant shifts in endothelial differentiation of f- versus MAB-MiPs 
either in vitro or in vivo. However, in murine muscles injected with 
canine cells, higher rates of MAB-MiP engraftment and regenera-
tion in skeletal muscle correlated with higher rates of engraftment 
in the pool of resident AP+ MABs. More comprehensive studies are 
thus required to shed light on the molecular cues that possibly dis-
criminate between pericytic and myogenic propensities in these 
cells. In this perspective, an intriguing experimental question 
would be whether reprogrammed MABs retain a similar propen-
sity, such as a that toward other mesodermal lineages (e.g., endo-
thelial, osteogenic, adipogenic), when generated from somatic 
MABs exposed to other differentiative cues. However, such an 
approach will necessarily face the potential restriction in general 
properties of transdifferentiated MABs, such as proliferation and 
susceptibility to reprogramming, which would influence the qual-
ity of iPSCs and possibly mask the changes in intrinsic propensity.
Several reports have recently pointed to the transient nature of 
epigenetic memory and its washout after continuous passaging (8). 
We cannot exclude the possibility that this could also be a limita-
tion in our system, since our experiments of morula aggregation, 
teratoma formation, and MiP isolation were conducted with iPSCs 
at low (≤5) passage numbers. However, passaging-induced fade-
out of epigenetic imprinting could, in principle, be compensated 
by the tremendous expansion capacity of both iPSCs and MiPs. In 
fact, under opportune conditions of reprogramming and expansion 
like cells. However, MAB-MiPs showed skewed levels of skeletal 
muscle commitment in vitro (Figure 12A). In addition, human f- 
and MAB-MiPs differentiated to a comparable extent toward oste-
ogenic, adipogenic, and endothelial cell lineages, thus recapitu-
lating the characteristics of murine and canine MiPs (Figure 12B). 
Finally, we used human MiPs to specifically address the question 
of whether, after MiPs fuse in vitro and in vivo, the presence of 
GFP in cardiac and skeletal myocytes is the result of unspecific 
GFP diffusion, or whether it correlates with specific lineage com-
mitment. To this end, we obtained single-cell clones of human 
GFP+ f- and MAB-MiPs and differentiated them in vitro with neo-
natal cardiomyocytes and myoblasts, both from rodents. Immu-
nostaining with human-specific Abs revealed that only when GFP+ 
MiPs fused with cardiomyocyte clusters or skeletal myotubes was 
the signal of human sarcomeric proteins detectable, and it largely 
colocalized with the GFP signal (Figure 12C), indicating specific 
myogenic commitment upon GFP diffusion. Thus, MAB-related 
enhanced myogenic propensity appeared evident and durable also 
in human iPSCs and MiPs. Moreover, human MiPs recapitulated, 
at least in vitro, the capability of dual differentiation toward the 
striated muscle lineages, with an enhanced propensity for skeletal 
myogenesis in human MAB-MiPs.
Discussion
Multitissue differentiation potential is one of the most appealing 
aspects of iPSC technology for MD treatments, in which com-
bined rescue of cardiac and skeletal muscle functionality is par-
amount (28). Yet the combination of safety and efficaciousness 
of iPSC-derived cells in vivo remains an important issue for the 
translation of these methods from bench to bedside (29). In this 
view, a refined understanding of the source-related retainment of 
myogenic propensity and its in vivo relevance may provide a rela-
tively easy way to tune the intrinsic fate of iPSCs and derived pro-
genitors by means of donor cell choice. Our results indicate that 
the enhanced myogenic propensity of MAB-derived iPSCs and 
MiPs correlates with the retained epigenetic cues of histone marks 
and DNA methylation of CpG islands upstream of key markers 
of lineage progression. Indeed, in our experimental settings, the 
permissive/activating epigenetic cues found on cardiomyogenic 
markers correlated with a robust cardiomyogenic potential of 
MiPs, especially as shown in vivo. Conversely, progeny-related 
retainment of different epigenetic signatures on skeletal muscle 
genes was associated with a differential intrinsic propensity of 
MiPs toward the skeletal muscle lineage. We are aware that our 
epigenetic analyses were limited to a small number of regulatory 
elements and genes and are thus only sufficient for describing a 
correlation between the differential propensity of f- and MAB- 
derived cells. In order to gain mechanistic insights into how the 
epigenetic imprinting is retained and causes the skew in intrinsic 
propensity, a more comprehensive, genome-wide approach will be 
needed. Importantly, such an approach will likely identify putative 
key regulators of myogenic bias retainment and, thereby, putative 
targets to specifically increase or decrease skeletal myogenic pro-
pensity during reprogramming and differentiation.
In our study, we used MAB-derived iPSCs and MiPs as 
sources of myogenic bias in the context of striated muscle regen-
eration and fibroblast-derived cells as controls. We chose this cell 
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was coherent across many parameters for both cardiac and skeletal 
muscles. This successfully addresses the main challenge facing the 
MiPs, namely, whether these novel progenitors are able to regener-
ate both striated muscle types with a combined, balanced outcome. 
In addition, both f- and MAB-MiPs appeared able to engraft both 
slow and fast muscle fibers and did not induce a quantitative shift 
in fiber type composition in engrafted muscles. Also, the off-target 
engraftment of MiPs after intracirculatory delivery appeared rare 
and restricted to vascular smooth muscle. Nevertheless, a better 
strategy to more efficiently infuse both types of striated muscle 
tissues with MiPs will likely increase the chances of greater func-
tional restoration. Also, a deeper understanding of MiP biology will 
enable us to appropriately engineer MiPs for improved regenerative 
outcomes. Furthermore, the safety and efficacy of the MiP strat-
egy will likely necessitate validation in large MD animal models in 
order to test its feasibility in human-sized striated muscles. In this 
view and with the goal of upgrading in vivo administration from 
targeted to systemic delivery, it will be of fundamental importance 
to identify and manipulate pathways that regulate MiP migration 
and homing.
Finally, the successful combination of MD mutation correc-
tion and in vivo regeneration of striatal muscle in immunodefi-
cient dystrophic mice paves the way for further exploration of 
MiP-based approaches for putative autologous treatments. In this 
perspective, it was intriguing to observe that human MiPs reca-
pitulated the dual myogenic commitment, even though our proof 
of principle was restricted to in vitro assessment. Therefore, a 
refined assessment of the in vivo regenerative potential of human 
MiPs will be crucial for progression along the translational path of 
MiP-based therapies for striated muscle regeneration.
Methods
Cell culture and isolation. Murine fibroblasts and MABs were isolated 
from 3 syngeneic C57/Bl6 male mice (obtained from internal stock 
at the KU Leuven Animal Facility). Murine fibroblasts were isolated 
by digesting minced tail tips in 0.1% collagenase IV (Thermo Fisher 
Scientific) in three 20-minute rounds of shaking at 37°C. Cells were 
single-cell cloned and expanded on gelatin-coated vessels in DMEM 
20% medium (high-glucose DMEM supplemented with 20% FBS, 
1% sodium pyruvate, 1% penicillin/streptomycin, 1% L-glutamine, 
1% nonessential amino acids [NEAA], and 0.2% 2-mercaptoethanol) 
(Thermo Fisher Scientific) in 5% O2/5% CO2 at 37°C and checked for 
homogeneous expression of CD90. Murine MABs were isolated as 
previously described (25). Briefly, tibialis anterior muscles were tis-
sue cultured in small pieces on collagen-coated 3.5-cm dishes (Nunc, 
Thermo Fisher Scientific) in DMEM 20% medium supplemented with 
5% penicillin/streptomycin and 0.5% gentamycin (Sigma-Aldrich). 
Cells propagating from the biopsies were then FACS sorted as an AP+ 
fraction using a PE-conjugated Ab (R&D Systems; catalog FAB1448P). 
AP+ MABs were single-cell cloned, then expanded and checked for 
homogeneous AP expression before passage number 3 by means 
of 5-bromo-4-chloro-3-indolyl phosphate (BCIP) staining (Sigma- 
Aldrich) and/or live staining (Thermo Fisher Scientific). MAB clones 
were expanded on collagen-coated vessels (Nunc, Thermo Fisher Sci-
entific) in DMEM 20% medium in 5% O2/5% CO2 at 37°C.
Murine cells were reprogrammed as previously described (11). 
Briefly, cells were transduced with retroviral particles carrying Oct4, 
in a limited number of passages, myogenic imprinting could prove 
durable up to the MiP stage, even under good laboratory practice/
good manufacturing practice (GLP/GMP) conditions. Moreover, 
of importance for putative future therapies is the notion that epige-
netic imprinting appears intrinsically more durable in human cells 
than in rodent cells (15). However, it is important to consider that 
epigenetic memory is not specifically tunable as such, at least not 
without the help of transgenic or genome-edited systems. Also, epi-
genetic bias is likely to vary in terms of imprinted genes according 
to the intrinsic status of the source cell and, therefore, to the cell 
preparation. Thus, it will be relevant for the field to use such skewed 
cellular systems to identify putative imprinted targets that affect 
cell potency. Nonintegrative manipulation of such candidates might 
then offer a more clinically oriented perspective for these studies.
The positive outcome we observed in treated dystrophic 
mice suggests that MiPs represent a promising tool for combined 
regeneration of both striated muscle types. In vitro and in vivo, 
MiPs were able to differentiate toward both cardiac and skeletal 
muscle lineages. Skeletal muscle differentiation of MiPs, particu-
larly of murine origin, seemed to correlate with expression levels 
of mesodermal transition markers, e.g., brachyury, and of lin-
eage-specific genes, e.g., Pax7. Despite the fact that no significant 
differences were found in brachyury expression when we analyzed 
the differentiating iPSC bulk cultures, isolated MAB-MiPs showed 
significantly higher expression levels of this gene as well as of Pax7 
when compared with f-MiPs in both whole-cell pools and single-
cell clones. Intriguingly, restoring the expression levels of both 
genes — but not each singularly — in f-MiPs markedly increased 
skeletal muscle differentiation in vitro to levels comparable to 
those observed with MAB-MiPs. Further studies are needed to 
determine whether such manipulation might also prove useful in 
in vivo settings. With regard to the spontaneous cardiac differenti-
ation of MiPs, their high efficiency in generating cardiac-like cells 
in vitro was counterbalanced by their immature state (absence of 
spontaneous beating, immature pattern of terminal markers). 
Further studies are thus required to augment the terminal matu-
ration of MiP-derived myocytes in vitro. However, the coculture 
systems we used showed functional maturation of the MiPs toward 
both striated muscle lineages, e.g., beating cardiomyocytes and 
dystrophin-expressing myotubes. Albeit more heterogeneous, the 
coculture systems enabled us to address the question of whether 
MiPs are competent for regeneration in the presence of surround-
ing myocytes, thus mimicking in vivo engraftment. Consistent with 
this notion, both murine and canine MiPs were indeed able to drive 
the combined functional regeneration of both striated muscle types 
in vivo in murine models of simultaneous delivery. Comparing the 
in vitro coculture and the robust rates of in vivo engraftment, we 
can speculate that MiPs mainly regenerate the striated muscles in 
vivo by fusing with resident myocytes and then differentiating into 
myocytes and regenerating  the host muscle, as proven by reexpres-
sion of the missing therapeutic proteins (Sgcb, dystrophin), colo-
calization of GFP and MiP-specific sarcomeric proteins (human 
sarcomeric α-actinin [Sarc αAct]), and the improved functional 
performance. In this regard, the levels of MiP-induced functional 
repair in dystrophic or injured mice were lower than WT levels in 
comparable experimental conditions (e.g., fractional shortening, 
~42%; run time, ~110 min). However, the functional improvement 
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0.6% pancreatin (Sigma-Aldrich) and subjected to three 20-minute 
rounds of shaking in a 37°C-warmed water bath. The neonatal rat car-
diomyocytes were further purified using a Percoll gradient (0.458 g/ml 
to 0.720 g/ml; GE Healthcare). MiPs were seeded in coculture with 
rat neonatal cardiomyocytes with a 1:10 MiP/cardiomyocyte ratio in 
cardiomyocyte maintenance medium (high-glucose DMEM supple-
mented with 18% medium 199, 5% horse serum, 5% FBS, 1% penicillin/ 
streptomycin, and 1% L-glutamine) (Thermo Fisher Scientific) on 
gelatin-coated vessels (Nunc, Thermo Fisher Scientific) for 72 hours 
in 5% O2/5% CO2 at 37°C. Cardiomyogenic spontaneous differentia-
tion was induced by seeding murine MiPs at low density (5,000 cells/
cm2) on collagen-coated vessels (Nunc, Thermo Fisher Scientific) in 
RPMI 20%/10% medium (RPMI supplemented with 20% FBS, 10% 
horse serum, 1% penicillin/streptomycin, and 1% L-glutamine) for 72 
hours in 5% O2/5% CO2 at 37°C, then further matured in DMEM 2% 
medium (high-glucose DMEM supplemented with 2% horse serum, 
1% penicillin/streptomycin, and 1% L-glutamine) for 24 to 48 hours in 
5% O2/5% CO2 at 37°C. Skeletal myogenic differentiation of murine 
MiPs was induced in coculture with C2C12 fetal myoblasts or through 
pulsed overexpression of Pax3 and Pax7. Murine MiPs were seeded in 
coculture with C2C12 fetal myoblasts with a 1:10 MiP/myoblast ratio in 
RPMI 20%/10% medium medium on collagen-coated vessels for 24 
hours, then differentiated in DMEM 2% medium for 96 to 120 hours in 
5% O2/5% CO2 at 37°C. Murine MiPs were pulsed with Pax3 and Pax7 
through transfection in proliferative conditions with two pSPORT6.1 
plasmids bearing Pax3 and Pax7 cDNA sequences and with Lipofect-
amine (Thermo Fisher Scientific) according to the manufacturer’s 
instructions. The murine MiPs were then differentiated for 10 days 
in DMEM 2% medium supplemented with 1% insulin-transferrin- 
selenium (ITS) (Thermo Fisher Scientific), 100 ng/ml recombi-
nant noggin (Thermo Fisher Scientific), and 1 mM TGF-β inhibitor 
(Sigma-Aldrich; SB 431542). Transient overexpression of brachyury 
(pCMV6-Entry; Origene) and Pax7 (as mentioned above) in MiPs 
was achieved by Lipofectamine-based transfection of small amounts 
of plasmid, i.e., 100 ng brachyury-bearing and 120 ng Pax7-bearing 
plasmids per 24-well plate (cells transfected with the empty vectors 
were used as a control). Then, transfected cells were harvested after 
48 hours, analyzed for gene induction, and plated for coculture with 
myoblasts and for spontaneous differentiation. Osteogenic and adi-
pogenic differentiation of murine MiPs was induced using osteogenic 
and adipogenic kits (EMD Millipore) according to the manufacturer’s 
instructions. Smooth muscle differentiation was performed on MiPs 
seeded at low density on collagen-coated vessels in DMEM 2% supple-
mented with 50 ng/ml TGF-β1 (Peprotech). Endothelial differentiation 
was induced by seeding 105 MiPs per well, previously cultured for 2 
passages in EBM2 medium (Lonza) on fibronectin-coated plastic, then 
in EBM2 medium in 48-well plates (Nunc, Thermo Fisher Scientific) 
coated with a thin layer of Geltrex (Thermo Fisher Scientific). Tubu-
lar structures were well formed and apparent 48–72 hours after seed-
ing, and 10 μg/μl Dil-Ac-LDL (Thermo Fisher Scientific) was supple-
mented for 4 hours in culture before proceeding to immunostaining.
Canine and human fibroblasts and MABs were isolated as pre-
viously reported (25) and under conditions essentially analogous to 
those for the murine cells described above. The medium for isolating 
and growing canine and human MABs consisted of IMDM 10% supple-
mented with 10% FBS, 1% penicillin/streptomycin, 1% L-glutamine, 
1% sodium pyruvate, 1% NEAA, 1% ITS supplement (Thermo Fisher 
Sox2, Klf4, and cMyc cDNA sequences (pMX vectors; Addgene) and 
seeded at low confluence on a feeder layer of mitomycin-treated primary 
murine embryonic fibroblasts (iMEFs). Embryonic stem cell–like (ESC-
like) colonies were manually picked 3 to 4 weeks after transduction, clon-
ally expanded, and characterized for pluripotency marker expression.
Murine f- and MAB-iPSCs were cultured on a feeder layer of iMEFs 
in iPSC medium consisting of high-glucose DMEM supplemented with 
20% knockout serum, 1% sodium pyruvate, 1% penicillin/streptomy-
cin, 1% L-glutamine, 1% NEAA, 0.2% 2-mercaptoethanol, and 100 U/
ml leukemia inhibitory factor (LIF) (all from Thermo Fisher Scientific 
except LIF, which was purchased from EMD Millipore) in 5% O2/5% 
CO2 at 37°C. GFP+ iPSCs were obtained by transfecting the cells with 
a piggyBac transposon–bearing GFP and a dedicated transposase-
expressing plasmid, provided by M. Chuah and T. Vandendriessche 
(Department of Gene Therapy and Regenerative Medicine, VUB Uni-
versity, Brussels, Belgium). GFP+ cells were then isolated by FACS 10 
days after transfection. Once the feeder layer was removed by brief 
preplating on gelatin-coated plastic vessels (Nunc, Thermo Fisher Sci-
entific), GFP+ iPSCs were induced to form embryoid bodies (EBs) in 
suspension culture in nonculture-treated plastic dishes (105 cells in an 
8-ml/10-cm dish; BD) in DMEM 20% medium for 72 hours in 5% O2/5% 
CO2 at 37°C. Subsequently, EBs were collected, centrifuged, disaggre-
gated by thorough pipetting, resuspended as single cells and seeded for 
suspension culture in the same number of nonculture-treated dishes 
used in the previous step, and placed in EB medium containing Iscove’s 
modified Dulbecco’s medium (IMDM) supplemented with 15% FBS, 
1% penicillin/streptomycin, 1% L-glutamine (all from Thermo Fisher 
Scientific), 4.5 mM thyoglycerol, 50 mg/ml ascorbic acid, and 200 
mg/ml holo-transferrin (all from Sigma-Aldrich) for 72 hours in 5% 
O2/5% CO2 at 37°C. Next, EBs were gently collected, with care taken 
to avoid disruption, and plated on an equal number of collagen-coated, 
culture-treated plastic dishes (Nunc, Thermo Fisher Scientific) in EB 
medium for 72 hours in 5% O2/5% CO2 at 37°C. At this stage, cells were 
gently detached with TrypLE (Thermo Fisher Scientific) and FACS 
sorted on a BD FACSAria III using APC-conjugated anti-CD140a Ab 
(eBioscience). Both CD140a+ and CD140a– fractions were collected 
for further positive and negative selections, respectively, and seeded 
in DMEM 20% medium on collagen-coated 3.5-cm dishes and incu-
bated in 5% O2/5% CO2 at 37°C. Upon 90% confluence, in conditions 
similar to those of the first sorting step, cells were further purified using 
APC-conjugated CD140b Ab, and, as a last step, CD44 Ab (eBioscience; 
catalogs 17-1401-81, 17-1402-80, and 17-0441-81). After the three sort-
ing steps, CD140+CD140b+CD44+ cells (murine MiPs) were cultured 
on collagen-coated, culture-treated plastic vessels (Nunc, Thermo 
Fisher Scientific) in DMEM 20% medium in 5% O2/5% CO2 at 37°C. 
Single-cell cloning was performed by seeding murine MiPs at a den-
sity of 0.5 cells per well in flat-bottomed, collagen-coated 96-multiwell 
plates (Nunc, Thermo Fisher Scientific). After 9 to 10 days, proliferat-
ing clones were then expanded on 6-well plates for qPCR-based char-
acterization and injection. Cardiomyogenic differentiation of murine 
MiPs was induced in coculture with neonatal rat cardiomyocytes or via 
spontaneous differentiation. Neonatal rat cardiomyocytes were har-
vested from newborn rat pups within 24 hours of birth by digesting the 
minced hearts in ADS buffer (tissue culture water supplemented with 
0.0085% NaCl, 0.0005% KCl, 0.00015% monohydrated NaH2PO4, 
0.00125% monohydrated MgSO4, 0.00125% glucose, and 0.00595% 
HEPES) (Sigma-Aldrich) supplemented with 0.4% collagenase II and 
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Abs (1 μg/10 μg) anti-K9me3 (repressive mark), anti-K4me2 (permis-
sive mark), and anti-K27ac (active mark) (all obtained from Active 
Motif; catalogs 39142, 39133, and 39765) were used in the ChIP exper-
iments, and protein A–coated sepharose beads (GE Healthcare) were 
used for the subsequent pulldown. IgG isotype (eBioscience) was used 
as a negative ChIP control. The initial sonicated gDNA fragment sus-
pension (5 μl of 100 μl) was used as a reference input. Purification of 
ChIP and input DNA was performed using a MinElute kit (QIAGEN), 
and quantification as a percentage of input was performed by SYBR 
Green qPCR under the conditions described above. Statistical analysis 
was performed using three qPCR replicates per cell clone (3 clones per 
cell type obtained from independent donors).
Western blot (WB) analyses were performed on 50 μg cell or 
tissue lysate (100 μg for dystrophin analysis) according to the com-
monly used procedures in 10% acrylamide (6% for dystrophin anal-
ysis) hand-cast gels. The following Abs and relative dilutions were 
used: mouse anti–Sarc αAct (Abcam; catalog ab72592; 1:500); mouse 
anti-Sgcb (Novocastra, Leica Biosystems; catalog B-SARC-CE; 
1:500); mouse anti–dystrophin 3 (interacting with canine and human 
isoforms; Novocastra, Leica Biosystems; catalog DYS3-CE-S; 1:500); 
rabbit anti-GAPDH (Sigma-Aldrich; catalog G9545; 1:1,000); and 
secondary HRP-conjugated Abs (Santa Cruz Biotechnology Inc.; cat-
alogs sc-2005 and sc-2004; 1:500). Bands were detected and imaged 
with a Bio-Rad Gel Doc using a Pico substrate (Thermo Fisher Sci-
entific) and a Dura substrate for dystrophin analysis. Densitometric 
analyses were performed on gels loaded, blotted, and detected in par-
allel with Quantity One software (Bio-Rad).
In vivo injections and functional analyses. Teratoma formation 
was testing by s.c. injecting 3 × 105 iPSCs at passage 3 into immu-
nodeficient Rag2-null γc-null mice (The Jackson Laboratory), using 
either Matrigel-free murine iPSCs or canine and human iPSCs that 
were grown in a 1:1 v/v matrigel/cell suspension. Teratomas were 
isolated 4–6 weeks after injection for murine iPSCs and 6–8 weeks 
after injection for canine and human iPSCs and were further tested 
for histological, immunostaining, or molecular analyses. Morula 
aggregation was performed by aggregating trypsin-pretreated GFP+ 
iPSCs (<10-cell clumps; C57/Bl6 background; passages 3–5) with 
CD1 morulae (KU Leuven Animal Facility, internal stock mice) freed 
from the zona pellucida by acidic Tyrode’s solution and cultured 
in KSOM medium (Specialty Media) under preequilibrated min-
eral oil (Sigma-Aldrich) at 37°C in 5% CO2. The next day, embryos 
were transferred into the uterus of pseudopregnant Swiss females 
(KU Leuven Animal Facility, internal stock mice). Chimerism was 
detected by GFP stereofluorescence, anti-GFP staining of cryosec-
tions, and coat chimerism after birth and in the chimeric F1 litter. 
Dystrophic cardiomyopathic Sgcb-null mice (23) were divided into 
randomized groups at 3 months of age (n = 8, sham; n = 8, f-MiPs; 
n = 8, MAB-MiPs for bulk injections; n = 5 per cohort for single-cell 
clone injections) and injected with GFP+ murine MiPs (passages 3–7). 
All mouse groups were kept on cyclosporine-based immunosuppres-
sive treatment throughout the entire experiment. MiPs were exposed 
to RPMI 20%/10% medium for 48 hours, then injected in parallel 
into the left ventricular myocardium and into both femoral arteries 
of each animal under isofluorane anesthesia (5 × 105 cells/5 × 2.5 μl 
in the myocardium; 5 × 105 cells/100 μl per femoral artery). Sham 
controls received equal treatment and amounts of cell-free saline 
solution. Engraftment, regeneration, and functional outcomes were 
Scientific), 0.2% 2-mercaptoethanol, and 5 ng/ml bFGF (PeproTech). 
Reprogramming of canine and human cells was performed under con-
ditions analogous to those for murine cell reprogramming, using ret-
roviral particles carrying human OCT4, SOX2, KLF4, and cMYC and 
cDNA sequences (pMX vectors; Addgene). Cells were seeded at low 
confluence on a feeder layer of iMEFs. ESC-like colonies were man-
ually picked 3–4 weeks after transduction, clonally expanded, and 
characterized for pluripotency marker expression. Canine and human 
f- and MAB-iPSCs were cultured on a feeder layer of iMEFs in hiPSC 
medium (DMEM-F12 supplemented with Ham’s F12 Nutrient Mix-
ture [Thermo Fisher Scientific], 20% knockout serum, 1% penicillin/
streptomycin, 1% L-glutamine, 1% NEAA, 0.2% 2-mercaptoethanol, 
and 5 ng/ml bFGF [PeproTech]). Differentiation of canine and human 
f- and MAB-iPSCs toward MiPs was performed under conditions anal-
ogous to those for murine iPSCs, except for the first step of EB for-
mation in hiPSC medium and for a 96-hour duration for each of the 
three steps. Canine and human MiPs were FACS sorted under condi-
tions analogous to those for murine MiPs, using APC-conjugated anti-
CD140a, anti-CD140b (Antibodies Online; catalogs ABIN910520 and 
ABIN457302), and anti-CD44 Abs (eBioscience; catalog 17-0441-81). 
As freeze/thaw cycles are detrimental to canine cell survival and prop-
erties, experiments with canine iPSCs and MiPs were performed with 
reprogrammed/isolated cells under continuous passaging. Finally, 
culture of canine and human MiPs and their differentiation toward the 
different mesodermal lineages (cardiomyogenic, skeletal myogenic, 
osteogenic, adipogenic, and smooth muscle) were performed follow-
ing the procedures optimized for murine MiPs.
Molecular assays. Gene expression levels were assayed by SYBR 
Green qPCR on 1:5 diluted cDNA obtained from 1 μg total RNA 
(SYBR Green mix, SSIII cDNA production kit, and RNA extraction 
kit; all from Thermo Fisher Scientific) using a ViiA 7 384 plate reader 
(Thermo Fisher Scientific) at a final primer concentration of 100 nM; a 
final volume of 10_l; a Pgk/PGK internal reference; and a thermal pro-
file of 15 seconds at 95°C and 60 seconds at 60°C, ×40 cycles. Primers 
are listed in the Supplemental material.
Methylation patterns were assayed by means of bisulphite sequenc-
ing of CpG islands located 10 kb upstream of the transcription start 
site of the target genes (according to MethPrimer, ref. 36). Genomic 
DNA (gDNA) was isolated using a Genomic DNA Mini Kit (Thermo 
Fisher Scientific), then 1 μg/20 μl was bisulphite converted using an 
EpiTect Bisulphite Kit (QIAGEN). Single CpG island amplicons were 
amplified by PCR (final primer concentration: 330 nM; final volume: 
20 μl; thermal profile: 30 seconds at 95°C, 60 seconds at 55°C, and 60 
seconds at 72°C, ×40 cycles) on a T3000 Thermocycler (Biometra) 
using Taq polymerase (Thermo Fisher Scientific), then gel extracted 
using a Gel Extraction Kit (Thermo Fisher Scientific) and ligated into 
pGEM plasmids via TA cloning (Promega). Sequencing reactions were 
prepared with T7 and SP6 primers using BigDye Terminator v3.1 Cycle 
Sequencing and BigDye Exterminator kits (Thermo Fisher Scientific), 
sequenced on an Applied Biosystems ABI 3100 Sequencer (performed 
at the Genomics Core, UZ-KU Leuven, Leuven, Belgium), and ana-
lyzed with QUMA on-line software (37). Statistical analysis was per-
formed on average methylation values of 5 sequences per cell clone (3 
clones per cell type obtained from independent donors).
Histone mark levels were assayed by ChIP on the same CpG 
islands assayed by bisulphite sequencing, adapting previously 
described conditions (38) to 5 × 106 cell pellets. The DNA polyclonal 
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Discovery V12 microscope with Axio Imaging software (2-second 
exposure for GFP, 0.2-second exposure for bright-field, semire-
fringent bottom). Immunofluorescence staining was performed 
following the commonly used Triton-based (Sigma-Aldrich) per-
meabilization steps, donkey serum (Sigma-Aldrich) background 
blocking, overnight incubation with primary Ab at 4°C, a 1-hour 
incubation with 1:500 Alexa Fluor–conjugated donkey secondary 
Abs (Thermo Fisher Scientific), and a final counterstaining with 
Hoechst. The primary Abs and relative dilutions used were as fol-
lows: rabbit anti-nanog (Abcam; catalog ab80892; 1:500); mouse 
anti–TRA-1-60 (Santa Cruz Biotechnology Inc.; catalog sc-21705; 
1:100); rabbit anti-laminin (Sigma-Aldrich; catalog L9393; 1:300); 
goat anti-GFP (Abcam; catalog ab5450; 1:500); mouse anti– 
myosin heavy chain (anti-MyHC) (Developmental Studies Hybri-
doma Bank [DSHB]; MF20; 1:3); mouse anti–Sarc αAct (Abcam; cat-
alog ab72592; 1:300); rabbit anti-Myocd (Santa Cruz Biotechnology 
Inc.; catalog sc-33766; 1:100); mouse anti-Sgcb (Novocastra, Leica 
Biosystems; catalog B-SARC-CE; 1:100); mouse anti-calponin (Dako; 
catalog M3556; 1:300); canine- and human-specific mouse anti– 
dystrophin 3 (Novocastra, Leica Biosystems; catalog DYS3-CE-S; 
1:100); mouse anti-Pax3 (R&D Systems; catalog MAB2457; 1:300); 
mouse anti-AP (R&D Systems; catalog FAB1448P; 1:500); mouse 
anti-Pax7 (DSHB; catalog PAX7; 1:10); mouse anti–slow MyHC 
(Sigma-Aldrich; catalog M8421; 1:400); mouse anti–fast MyHC 
(Sigma-Aldrich; catalog M4276; 1:400); rabbit anti–human Sarc αAct 
(Abcam; catalog ab62298; 1:300); and mouse anti–α–smooth muscle 
actin (anti–α-SMA) (Sigma-Aldrich; catalog A2547; 1:300). Imaging 
was performed on an ECLIPSE Ti microscope with Image-Pro Plus 
6.0 software (both from Nikon). Quantitation of engraftment and sat-
ellite cells and fibers was performed with ImageJ software (NIH) on 
at least 10 fields across the left ventricle and gastrocnemius muscle.
TALEN-mediated genome editing. GRMD mutation (A→G transi-
tion, ref. 39) was checked by gDNA sequencing in our WT and GRMD 
canine cell samples. TALEN vectors were designed to recognize tar-
get regions at +33 nt and +66 nt downstream of the mutation site, and 
a donor matrix was designed to carry the therapeutic G→A transition 
at +0 nt and a silent mutation at +63 nt from the mutation site (A→G) 
in order to introduce a single SphI restriction site (Cellectis). TALEN 
vectors (1 μg/plasmid), donor matrix (3 μg), and a GFP-carrying plas-
mid (1 μg) were nucleofected into canine GRMD iPSCs (106 cells/800 
μl phenol red–free RPMI medium; Thermo Fisher Scientific) using 
the Gene Pulser Xcell (BioRad). Putative single-cell, nucleofected, 
transiently GFP+ clones were selected, expanded, recloned by single-
cell dilution, and checked by SphI assay and by sequencing. An SphI 
assay was performed on 0.5 μg PCR-amplified, gel-extracted gDNA 
amplicons (primers: forward, TGAAAAGTGTTATTGAGGGGTAA; 
reverse, TCCAGAAATGTACCGACCTT; thermal profile: 30 seconds 
at 95°C, 60 seconds at 57°C, and 60 seconds at 72°C, ×40 cycles) 
by overnight incubation at 37°C with 5 U SphI isoschizomer (PaeI; 
Thermo Fisher Scientific) in a 30-μl final volume reaction. Sequenc-
ing was performed on TA-cloned amplicons under the conditions 
described above (40 sequences/clone).
Statistics. The sample size for in vitro and in vivo experiments 
was calculated using a Sample Size Calculator (http://www.stat.ubc.
ca/~rollin/stats/ssize/index.html; parameters: power.80; alpha.05). 
When applicable, sample size analysis was based on average values 
obtained from preliminary optimization and validation trials. For 
investigated 4 and 8 weeks after injection. Muscle force and off- 
target engraftment analyses were conducted 8 weeks after injection. 
Immunodeficient Rag2-null γc-null mice (The Jackson Laboratory) 
were divided into randomized groups at 2 months of age (n = 7, sham; 
n = 7, f-MiPs; n = 7, MAB-MiPs) and injected with canine MiPs (pas-
sages 3–7). Ten days before cardiac injection, the hind limb skeletal 
muscles of mice from all groups were locally injected with cardi-
otoxin (50 μl/muscle, 10 μM solution). Seven days before cardiac 
injection, mice were injected with cells or sham into both femoral 
arteries (5 × 105 cells/100 μl per femoral artery) under isofluorane 
anesthesia. Cardiac injection was performed directly into the left 
ventricular myocardium (5 × 105 cells/10 μl) 1 hour after coronary 
artery ligation. Engraftment, regeneration, and functional outcomes 
were investigated 4 weeks after injection. Immunodeficient, dystro-
phic Sgcb-null Rag2-null γc-null mice were generated by crossing the 
aforementioned dystrophic and immunodeficient mice strains until 
achieving homozygosity in all mutated alleles, as determined by PCR 
of gDNA using dedicated JAX primers (The Jackson Laboratory). Sgcb- 
null Rag2-null γc-null mice were injected and analyzed according 
to the procedures used for dystrophic mice. High-resolution digital 
ultrasound images were obtained by an experienced echocardiog-
rapher using the Vevo 2100 Imaging System (VisualSonics) with a 
30-MHz probe. Mice were anesthetized using 1% isofluorane in oxy-
gen, positioned on the system’s heating pad in order to maintain nor-
mothermia, and continuously monitored. Prewarmed ultrasound gel 
was applied on the shaved thorax. B-mode–based 3D reconstruction 
was performed using the VisualSonics rail system with a fixed probe, 
with ECG and respiratory gating. Fractional shortening (FS) was cal-
culated on the basis of left ventricular internal dimension in diastole 
and systole (LVIDd/s) values, whereas end-diastolic volume (EDV), 
cardiac output (CO), and stroke volume (SV) were calculated on the 
basis of 3D analysis. Raw data were collected in a blinded fashion. 
Treadmill testing was conducted on a 10° incline treadmill belt with 1 
m/min2 acceleration at a starting speed of 10 m/min. The mouse run 
was stopped after 5 or more consecutive seconds on the pulsed grill. 
Muscle force assessment was performed on freshly isolated EDL 
muscles upon sacrifice, using a 1200A in vitro muscle test system 
(Aurora Scientific). Muscle force was probed upon 20 iterated bouts 
of isometric contractions (200-Hz, 80-V, 0.5-millisecond stimula-
tion, 0.5-second tetanus at 10-second intervals in 30°C) in dedicated 
buffer (1.2 mM KH2PO4, 0.57 mM MgSO4*7H2O, 2 mM CaCl2*2H2O, 
10 mM HEPES, 0.5 mM MgCl2*6H2O, 0.5 mM MgCl2*6H2O, 4.5 mM 
KCl, 120 mM NaCl, 0.7 mM Na2HPO4, 1.5 mM NaH2PO4, 10 mM 
D-glucose, and 15 mM NaHCO3, pH 7.3; Sigma-Aldrich). Data were 
analyzed as the percentage of maximum absolute force of the input 
sham muscles. CK levels were measured under resting conditions 
(>24 hours after the last treadmill test) in serum obtained from more 
than 50 μl blood (withdrawn from the tail vein). CK level quantita-
tion was performed using the Creatine Kinase Activity Colorimetric 
Assay kit (BioVision) according to the manufacturer’s instructions 
for sample preparation and standard curve assessment.
Stereomicroscopic and immunofluorescence analyses. Whole fluo-
rescence imaging of injected/chimeric tissues and embryos was 
performed on an Olympus SZX12 stereomicroscope with analySIS 
getIT software (2-second exposure for GFP, 0.2-second exposure for 
bright-field, semirefringent bottom) for chimeric embryos and tis-
sues and murine MiP in vivo experiments and with a Zeiss SteREO 
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statistical comparisons involving chimeric mice, a Mann-Whitney 
U test was applied and significance scored when the P value was 
less than 0.05. For in vivo analyses, a Kruskal-Wallis test followed 
by Mann-Whitney U test comparing 2 target populations were per-
formed, and significance was scored when P was less than 0.05 for 
both tests. For gene expression analyses, 2-way ANOVA was applied 
to patterns measured over time (significance was scored when P 
was less than 0.05 for both interaction [cells] and column [stages] 
parameters), and an unpaired homoscedastic t test was applied to f- 
versus MAB-MiP comparisons (a P value of less than 0.05 was con-
sidered significant). For methylation pattern analyses, 1-way ANOVA 
with Bonferroni’s multiple comparisons test was applied to methy-
lation values expressed as a percentage of methylated CpGs versus 
total CpGs, and significance was achieved when P was less than 
0.05. For histone mark analyses, 2-way ANOVA with Bonferroni’s 
multiple comparisons test was applied to histone enrichment values 
expressed as a percentage of input, and significance was achieved for 
Q1 and Q2 when P was less than 0.05 for at least 2 of 3 histone mark 
data pools. All statistical analyses were conducted using GraphPad 
Prism 5.0 (GraphPad Software).
Study approval. All protocols and experiments involving mice and 
murine sampling were performed in compliance with Belgian law 
and with approval of the ethics committee of KU Leuven. Collection 
of canine samples was performed in compliance with French law and 
with approval of the ethics committee of the Maison Alford Veterinary 
School. Human fetal tissues were obtained from patients who required 
an induced abortion during the first trimester at IRCCS University 
Hospital San Matteo Foundation, where the surgical termination of 
pregnancy was also performed. The patients included in the study pro-
vided written informed consent before the tissue collection, and the 
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